Hypersensitivity pneumonitis: An infrequent cause of chronic lung fibrosis in Africa?
Article Sidebar
Main Article Content
Abstract
-
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
How to Cite
References
King TE jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370(22):2083-2092. https://doi.org/10.1056/NEJMoa1402582
Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370(22):2071-2082. https://doi.org/10.1056/ NEJMoa1402584
Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis- associated interstitial lung disease. N Engl J Med 2019;380(26):2518-2528. https:// doi.org/10.1056/NEJMoa1903076
Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 2019;381(18):1718-1727. https://doi.org/10.1056/ NEJMoa1908681
Seixas E, Ferreira M, Serra P, Aguiar R, Cunha I, Ferreira PG. Criteria for progressive fibrotic hypersensitivity pneumonitis in a Portuguese patient cohort. Afr J Thoracic Crit Care Med 2022;28(4):161-164. https://doi.org/10.7196/AJTCCM.2022.v28i4.250
Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2022;205(9):e18-e47. https://doi. org/10.1164/rccm.202202-0399ST
Wells AU, Flaherty KR, Brown KK, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases – subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: A randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med 2020;8(5):453-460. https://doi.org/10.1016/ S2213-2600(20)30036-9
Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials. Lancet 2011;377(9779):1760- 1769. https://doi.org/10.1016/S0140-6736(11)60405-4
Behr J, Prasse A, Kreuter M, et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): A double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med 2021;9(5):476-486. https://doi.org/10.1016/S2213-2600(20)30554-3
Morell F, Villar A, Montero M-A, et al. Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: A prospective case-cohort study. Lancet Respir Med 2013;1(9):685-694. https://doi.org/10.1016/S2213- 2600(13)70191-7
Ohtani Y, Ochi J, Mitaka K, et al. Chronic summer-type hypersensitivity pneumonitis initially misdiagnosed as idiopathic interstitial pneumonia. Intern Med 2008;47(9):857-862. https://doi.org/10.2169/internalmedicine.47.0656
Tateishi T, Johkoh T, Sakai F, et al. High-resolution CT features distinguishing usual interstitial pneumonia pattern in chronic hypersensitivity pneumonitis from those with idiopathic pulmonary fibrosis. Jpn J Radiol 2020;38(6):524-532. https://doi. org/10.1007/s11604-020-00932-6
Wright JL, Churg A, Hague CJ, Wong A, Ryerson CJ. Pathologic separation of idiopathic pulmonary fibrosis from fibrotic hypersensitivity pneumonitis. Mod Pathol 2020;33(4):616-625. https://doi.org/10.1038/s41379-019-0389-3
Fernández Pérez ER, Swigris JJ, Forssén AV, et al. Identifying an inciting antigen is associated with improved survival in patients with chronic hypersensitivity pneumonitis. Chest 2013;144(5):1644-1651. https://doi.org/10.1378/chest.12-2685
Kaul B, Cottin V, Collard HR, Valenzuela C. Variability in global prevalence of interstitial lung disease. Front Med (Lausanne) 2021;8:751181. https://doi. org/10.3389/fmed.2021.751181
Ainslie GM. Bird fancier’s hypersensitivity pneumonitis in South Africa: Clinical features and outcomes. S Afr Respir J 2013;19(2):48-53.
SwinglerGH.Summer-typehypersensitivitypneumonitisinsouthernAfrica:Areport of 5 cases in one family. S Afr Med J 1990;77(2):104-107.
AndoM,SugaM,NishiuraY,MiyajimaM.Summer-typehypersensitivitypneumonitis. Intern Med 1995;34(8):707-712. https://doi.org/10.2169/internalmedicine.34.707
Andronikou S, Goussard P, Gie RP. Not all children with nodular interstitial lung
patterns in South Africa have TB – a rare case of paediatric ‘Bird Fanciers’ disease’. Pediatr Pulmonol 2011;46(11):1134-1136. https://doi.org/https://doi.org/10.1002/ ppul.21473
Jeena PM, Coovadia HM, Thula SA, Blythe D, Buckels NJ, Chetty R. Persistent and chronic lung disease in HIV-1 infected and uninfected African children. AIDS 1998;12(10):1185-1193. https://doi.org/10.1097/00002030-199810000-00011
Fernández Pérez ER, Travis WD, Lynch DA, et al. Diagnosis and evaluation of hypersensitivity pneumonitis: CHEST Guideline and Expert Panel report. Chest 2021;160(2):e97-e156. https://doi.org/10.1016/j.chest.2021.03.066
Raghu G,Remy-Jardin M, Ryerson CJ, et al.Diagnosis of hypersensitivity pneumonitis in adults: An official ATS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2020;202(3):e36-e69. https://doi.org/10.1164/rccm.202005-2032ST